Discontinuation of ASP0598 Development for Chronic Tympanic Membrane Perforation

An individual drug development program involving the discontinuation of Phase I development of ASP0598 for chronic tympanic membrane perforation.

Companies1How many companies write about this.

Threads1One company can carry more than one thread here.

PeriodFY2024 →Last written FY2024

Directionhurts0 helps · 1 hurts · 0 flat

Loading